Navigation Links
uniQure Licenses RNA Interference Technology to Advance Huntington's Disease Program
Date:12/5/2012

echnology: DNA-directed RNA interference (ddRNAi) - sometimes called expressed RNAi. The technology's potential to address unmet medical needs and to cure disease results from its demonstrated ability to permanently silence genes which cause the condition. Importantly, this technology's target gene and related gene pathways will rarely have presented as a therapeutic avenue for research for the traditional small molecule agents, currently accounting for the majority of today's pharmaceutical products.

Founded in 1997 and trading publicly since 2001, Benitec Biopharma trades on the Australian Securities Exchange (ASX) under the symbol "BLT".  Benitec aims to deliver a range of novel ddRNAi-based therapeutics to the clinic in partnership with the pharmaceutical industry. Besides a focused R&D strategy in infectious diseases, cancer and chronic cancer-associated pain, Benitec Biopharma is pursuing programs with licensees that have advanced to pre-clinical and/or clinical trials.


'/>"/>
SOURCE uniQure B.V.
Copyright©2012 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. MetaStat, Inc. Executes Two New Licenses
2. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
3. Ventana licenses Gen-Probe IP for measuring ERG protein in prostate cancer patients
4. NTT DATA Licenses DATATRAK ONE™ for China
5. Neuralstem Grants First Licenses For CNS Therapy Surgical Devices
6. West Health Institute licenses Kinect-based physical therapy technology to Reflexion Health; West Health Investment Fund makes $4.25 million investment
7. Parios Regenerative Sciences, Inc. Licenses Exclusive Rights to Organic Nanotechnology for Skin Repair
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Fujitsu to Showcase Radiation-Hardened RFID Using FRAM Technology at Interphex 2012 in New York City, Booth #2430
10. SolutionStart Corp. Announces John Karagiannis as Vice President of Technology
11. Ultra Clean to Present at the Jefferies 2012 Global Technology, Media & Telcom Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013  Cephasonics, a ... today announced the introduction of the cQuest ... network-based communications with all cQuest Ultrasound™ hardware ... technology, including this new capability, at Hospitalar ... Brazil from May 21-24.  Cephasonics ...
(Date:5/21/2013)... May 21, 2013 BioElectronics Corp. (PINKSHEETS: ... electronic devices, announced that CEO, Andrew ... the FDA,s Medical Advisory Committee, Orthopedic and Rehabilitation ... for over the counter sales. "It,s ... medical device classification schema," Whelan said.  "While the ...
(Date:5/21/2013)...  Janssen R&D Ireland (Janssen) today announced primary ... 3 PROMISE study demonstrating that use of the ... virologic response 12 weeks after the end of ... 1 chronic hepatitis C adult patients with compensated ... when administered once daily with pegylated interferon and ...
Breaking Medicine Technology:Cephasonics Unveils Next-Generation Wireless-Imaging Technology for cQuest Ultrasound Hardware Platforms 2BioElectronics Presents FDA Reclassification Panel 2BioElectronics Presents FDA Reclassification Panel 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
... 7 NeuroVasx, Inc. announced,today the completion of a private ... of Minneapolis, MN and the Stephens Group of Little,Rock, AR. ... also announced completion of long term follow up on 20,patients ... which was completed in May. The company intends to announce ...
... Genomic Health,Inc. (Nasdaq: GHDX ) today announced ... DX(R) breast cancer test are scheduled to be ... Symposium, taking place,December 13-16, 2007. Oncotype DX is ... the likelihood of recurrence and the likelihood,of chemotherapy ...
Cached Medicine Technology:Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 2Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium 3
(Date:5/21/2013)... Long Beach, CA (PRWEB) May 21, 2013 ... the 3rd Annual EB-5 Investment Summit: Dealmakers Conference ... The Dealmakers Conference will focus on exploring alternative ... will provide the latest market, legal and economic ... executives, immigration and legal professionals within the EB-5 ...
(Date:5/21/2013)... Paris, France: The Orsiro stent, which is a ... polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting ... late lumen loss at nine months in the ... 2013 today. , The BIOFLOW-II substudy used intravascular ... quantitatively assess neointimal hyperplasia and stent apposition at ...
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 According to ... to Rethink the Use of Botox,” Botox injections ... since their approval in 2002 (Go to goo.gl/8iYbD). Although it ... quite popular with men. The injection makes facial wrinkles less ... Botox injection last for about three months. This means that ...
(Date:5/21/2013)... (PRWEB) May 21, 2013 The ... on cable networks and cable channels across the country, ... on its YouTube channel. The producers of the series ... in the shipping industry, the manufacturing industry, health-related companies, ... medical facilities and medical practitioners in all parts of ...
(Date:5/21/2013)... Diversity Focus, a non-profit organization striving ... residents in the Creative Corridor region, is releasing results ... news conference on Thursday, May 23rd at 10:30 a.m. ... 2008. , The survey is a critical ... efforts that attract, nurture and retain people of diverse ...
Breaking Medicine News(10 mins):Health News:Artisan Business Group to Host EB-5 Investment Conference in Long Beach, California 2Health News:Biodegradable stent proves non-inferior to drug-eluting stent 2Health News:Botox – Is the World’s Most Popular Cosmetic Procedure Safe? 2Health News:In View hosted by Larry King Announces New Videos on its YouTube Channel 2Health News:Diversity Focus Announces Results from 2013 Creative Corridor Survey at News Conference on Thursday, May 23rd at 10:30 a.m. 2
... as patient engagement, physician communication, and staff coordination may ... patient survival rates than others, according to a study ... Journal of the American Society of Nephrology (CJASN). ... figure out what top-performing dialysis units might be doing ...
... will receive a $2.3 million New Innovator Award today ... platelets and the technology that makes them work. ... to build platelets of biodegradable polymers, which link with ... and fellow researchers initially pursued the technology after seeing ...
... (BMC) has been awarded a four year, $5.7 million ... (NHLBI) for investigators from Boston University School of Medicine ... Cardiovascular Outcomes and Disparities. The goal of the Center ... health reform on cardiovascular (CV) care and outcomes, and ...
... Gardner HealthDay Reporter , WEDNESDAY, Sept. 29 (HealthDay ... younger women finds that screening can lower the risk of ... The study, done in Sweden, found that women who were ... 1,250 women five times over a 10-year period would save ...
... Kang Zhang, MD, PhD, professor of ophthalmology at the ... director of UCSD,s Institute of Genomic Medicine, has been ... Zhang and co-principal investigators Sheng Ding, PhD, from ... the University of Washington, received the highest possible scores ...
... of immunotherapy to children with neuroblastoma, a nervous system ... and free of disease progression after two years, according ... School of Medicine and fellow institutions. The percentage rose ... to 66 percent for children receiving immunotherapy plus standard ...
Cached Medicine News:Health News:Why do some dialysis centers have higher survival rates? 2Health News:Researchers to study effects of Mass. health reform 2Health News:Mammograms Save Lives for Women in Their 40s, Study Says 2Health News:Mammograms Save Lives for Women in Their 40s, Study Says 3Health News:UCSD receives NIH Transformative R01 Award for stimulation of neuron regeneration in the retina 2Health News:UCSD receives NIH Transformative R01 Award for stimulation of neuron regeneration in the retina 3Health News:Addition of immunotherapy boosts pediatric cancer survival in children with neuroblastoma 2
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: